

Status: Effectivity information can only be shown for content published to the website.

Update information can only be shown for content published to the website.

Perindopril Erbumine Tablets

General Notices

Details for the public consultation of this monograph are as follows:

EAG/Panel/Working Party	Medicinal Chemicals 2
Contact Details	helen.corns@mhra.gov.uk rachael.feltham@mhra.gov.uk sophie.cherrington@mhra.gov.uk bpcom@mhra.gov.uk
Deadline for Comment	31 st December 2026
Target Publication Date (subject to change)	BP 2028
Notes	Revised monograph If limits are too restrictive, please provide batch/stability data to demonstrate that an increase is required. Dissolution Suitable column updated. Identification Test B removed to reduce testing burden. Related substances Limits revised and HPLC gradient updated.

Action and use

Angiotensin converting enzyme inhibitor.

DEFINITION

Perindopril Erbumine Tablets contain [Perindopril Erbumine](#).

The tablets comply with the requirements stated under [Tablets](#) and with the following requirements.

Content of perindopril erbumine, $C_{19}H_{32}N_2O_5, C_4H_{11}N$

92.5 to 105.0% of the stated amount.

IDENTIFICATION

Dissolve a quantity of the powdered tablets containing 50 mg of Perindopril Erbumine in 10 mL of [dichloromethane](#) and centrifuge for 5 minutes. Filter the supernatant liquid (Whatman GF/C is suitable), extract the filtrate with 10 mL of [water](#) and wash the upper aqueous layer with two 10-mL quantities of [hexane](#). Evaporate the aqueous layer to dryness on a water bath and dry the residue at 60° at a pressure not exceeding 0.7 kPa, taking care to avoid excessive heating. The [infrared absorption spectrum](#) of the residue, [Appendix II A](#), is concordant with the reference spectrum of perindopril erbumine (RS XXX).

TESTS

Dissolution

Comply with the requirements in the [dissolution test for tablets and capsules](#), [Appendix XII B1](#).

TEST CONDITIONS

- (a) Use Apparatus 2, rotating the paddle at 50 revolutions per minute.
- (b) Use 500 mL of 0.05M [hydrochloric acid](#), at a temperature of 37°, as the medium.

PROCEDURE

Carry out the method for [liquid chromatography](#), [Appendix III D](#), using the following solutions.

- (1) After 45 minutes withdraw a sample of the medium and filter. Dilute with 0.05M [hydrochloric acid](#), if necessary, to produce a solution expected to contain 0.0004% w/v of Perindopril Erbumine.
- (2) 0.0004% w/v of [perindopril erbumine BPCRS](#) in 0.05M [hydrochloric acid](#).

CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (7.5 cm × 4.6 mm) packed with [octadecylsilyl silica gel for chromatography](#) (3 µm) (Luna C18 is suitable).
- (b) Use isocratic elution and the mobile phase described below.
- (c) Use a flow rate of 2 mL per minute.
- (d) Use a column temperature of 40°.
- (e) Use a detection wavelength of 215 nm.
- (f) Inject 40 µL of each solution.

MOBILE PHASE

34 volumes of [acetonitrile R1](#) and 66 volumes of [water](#), adjusted to pH 2.0 with a mixture of equal volumes of [perchloric acid](#) and [water](#).

DETERMINATION OF CONTENT

Calculate the total content of perindopril erbumine, $C_{19}H_{32}N_2O_5 \cdot C_4H_{11}N$, in the medium from the chromatograms obtained and using the declared content of $C_{19}H_{32}N_2O_5 \cdot C_4H_{11}N$, in [perindopril erbumine BPCRS](#).

LIMITS

The amount of perindopril erbumine released is not less than 75% (Q) of the stated amount.

Related substances

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions in mobile phase A.

- (1) To a quantity of the powdered tablets containing 16 mg of Perindopril Erbumine, add 7 mL and mix with the aid of ultrasound. Dilute to 10 mL and filter.
- (2) Dilute 1 volume of solution (1) to 100 volumes.
- (3) 0.16% w/v of [perindopril for peak identification EPCRS](#).
- (4) 0.01% w/v of [perindopril impurity standard BPCRS](#).
- (5) Dilute 1 volumes of solution (2) to 5 volumes.

CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (15 cm × 4.0 mm) packed with spherical [octylsilyl silica gel for chromatography](#) (5 µm) (Inertsil C8 is suitable).
- (b) Use gradient elution and the mobile phase described below.
- (c) Use a flow rate of 1.0 mL per minute.
- (d) Use a column temperature of 60°.
- (e) Use a detection wavelength of 215 nm.
- (f) Inject 20 µL of each solution.

MOBILE PHASE

Mobile phase A [water](#) adjusted to pH 2.5 with a mixture of equal volumes of [perchloric acid](#) and [water](#).

Mobile phase B 0.03% v/v solution of [perchloric acid](#) in [acetonitrile R1](#).

Time (Minutes)	Mobile phase A (% v/v)	Mobile phase B (% v/v)	Comment
0-5	95	5	isocratic
5-60	95→40	5→60	linear gradient
60-65	40→95	40→5	linear gradient
65-70	95	5	re-equilibration

When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to perindopril erbumine (retention time about 25 minutes) are: impurity B, about 0.68; impurity K, about 0.72; impurity E, about 1.2; impurity C, about 1.3; impurity D, about 1.3; impurity F, about 1.6 and impurity H, about 1.8 (impurity H may be eluted as 1 or 2 peaks).

SYSTEM SUITABILITY

The test is not valid, unless in the chromatogram obtained with solution (3), the peak-to-valley ratio is at least 3, where H_p is the height above the baseline of the peak due to impurity B and H_v is the height above the baseline of the lowest point of the curve separating this peak from the peak due to impurity K.

LIMITS

Identify any peak corresponding to impurities B, E, F, H and K in the chromatogram obtained with solution (1), using the chromatogram obtained with solution (3).

Identify any peak corresponding to impurities C and D in the chromatogram obtained with solution (1), using the chromatogram obtained with solution (4).

In the chromatogram obtained with solution (1):

the area of any peak corresponding to impurity F is not greater than 3 times the area of the principal peak in the chromatogram obtained with solution (2) (3.0%);

the area of any peak corresponding to impurity B is not greater than 1.5 times the area of the principal peak in the chromatogram obtained with solution (2) (1.5%);

the area of any peak corresponding to impurity C or D is not greater than 0.6 times the area of the principal peak in the chromatogram obtained with solution (2) (0.6%);

the area of any peak corresponding to impurity E is not greater than 0.4 times the area of the principal peak in the chromatogram obtained with solution (2) (0.4%);

the area of any other secondary peak is not greater than 2 times the area of the principal peak in the chromatogram obtained with solution (5) (0.2%);

the sum of the areas of all the secondary peaks excluding any peaks corresponding to impurities B, C, D, E and F is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (1.0%).

Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (5) (0.1%).

ASSAY

Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions in mobile phase.

(1) To a quantity of the powdered tablets add sufficient of the mobile phase to produce a solution containing 0.004% w/v of Perindopril Erbumine, mix with the aid of ultrasound and filter.

(2) 0.004% w/v of perindopril erbumine BPCRS.

CHROMATOGRAPHIC CONDITIONS

The chromatographic conditions described under Dissolution may be used but with an injection volume of 20 μ L.

DETERMINATION OF CONTENT

Calculate the content of $C_{19}H_{32}N_2O_5$, $C_4H_{11}N$ in the tablets using the declared content of $C_{19}H_{32}N_2O_5$, $C_4H_{11}N$ in [*perindopril erbumine BPCRS*](#).

IMPURITIES

The impurities limited by the requirements of this monograph includes impurities B to F and impurities H and K listed under [Perindopril Erbumine](#).

DRAFT MONOGRAPH
SUBJECT TO CHANGE